FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rose, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rose, K. M.

The FASEB Journal, Vol 2, 2474-2478, Copyright © 1988 by The Federation of American Societies for Experimental Biology

REVIEWS

DNA topoisomerases as targets for chemotherapy

KM Rose
Department of Pharmacology, Medical School, University of Texas Health Science Center, Houston 77225.

DNA topoisomerases are ubiquitous enzymes that alter the configuration or topology of DNA. These enzymes play an important role in replicational, recombinational, and transcriptional events and are a key to cell growth processes. A number of therapeutically useful drugs apparently exert their effects by interfering with DNA topoisomerization reactions. Several inhibitors of bacterial DNA topoisomerase II (DNA gyrase) have been developed. Most of these possess a 4-quinolone nucleus and are highly bactericidal for a variety of microorganisms; at therapeutically effective levels, these compounds do not inhibit the human topoisomerases. Other drugs, structurally distinct from the DNA gyrase inhibitors, inhibit the human type II DNA topoisomerase. These drugs, including m-AMSA and VP16-23, are proving useful in the treatment of several neoplasms.


This article has been cited by other articles:


Home page
 J Oncol Pharm PractHome page
R van Gijn, R. Lendfers, J. Schellens, A Bult, and J. Beijnen
Dual topoisomerase I/II inhibitors
Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3): 92 - 108.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by The Federation of American Societies for Experimental Biology.